35 related articles for article (PubMed ID: 28151716)
1. Correction: The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
Clin Cancer Res; 2016 Nov; 22(22):5619. PubMed ID: 28151716
[No Abstract] [Full Text] [Related]
2. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter.
Leon LG; Funel N; Peters GJ; Avan A; Vistoli F; Boggi U; Giovannetti E
Clin Cancer Res; 2016 May; 22(10):2594. PubMed ID: 27179113
[No Abstract] [Full Text] [Related]
3. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors.
Scheible H; Kraetzer F; Marx A; Johne A; Wimmer E
Drug Metab Dispos; 2017 Feb; 45(2):174-182. PubMed ID: 27934635
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
6. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies.
Ravandi F; Pigneux A; DeAngelo DJ; Raffoux E; Delaunay J; Thomas X; Kadia T; Kantarjian H; Scheuenpflug J; Zhao C; Guo W; Smith BD
Blood Cancer J; 2015 Dec; 5(12):e375. PubMed ID: 26657199
[No Abstract] [Full Text] [Related]
7. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Macarulla T; Cervantes A; Tabernero J; Roselló S; Van Cutsem E; Tejpar S; Prenen H; Martinelli E; Troiani T; Laffranchi B; Jego V; von Richter O; Ciardiello F
Br J Cancer; 2015 Jun; 112(12):1874-81. PubMed ID: 25989270
[TBL] [Abstract][Full Text] [Related]
9. PIMASERTIB AND SEROUS RETINAL DETACHMENTS.
AlAli A; Bushehri A; Park JC; Krema H; Lam WC
Retin Cases Brief Rep; 2016; 10(2):191-6. PubMed ID: 26444523
[TBL] [Abstract][Full Text] [Related]
10. Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib.
Sala V; Gallo S; Gatti S; Medico E; Vigna E; Cantarella D; Fontani L; Natale M; Cimino J; Morello M; Comoglio PM; Ponzetto A; Crepaldi T
J Mol Cell Cardiol; 2016 Apr; 93():84-97. PubMed ID: 26924269
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.
Airiau K; Prouzet-Mauléon V; Rousseau B; Pigneux A; Jeanneteau M; Giraudon M; Allou K; Dubus P; Belloc F; Mahon FX
Oncotarget; 2016 Jan; 7(1):845-59. PubMed ID: 26625317
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of novel highly hydrophilic and non-ATP-competitive MEK1/2 inhibitor, SMK-17.
Kiga M; Tanzawa F; Iwasaki S; Inaba F; Fujiwara K; Iwadare H; Echigo T; Nakamura Y; Shibata T; Suzuki K; Yasumatsu I; Nakayama A; Sasazawa Y; Tashiro E; Imoto M; Kurakata S
Anticancer Drugs; 2012 Jan; 23(1):119-30. PubMed ID: 22008853
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect interactions between calcineurin-NFAT and MEK1-extracellular signal-regulated kinase 1/2 signaling pathways regulate cardiac gene expression and cellular growth.
Sanna B; Bueno OF; Dai YS; Wilkins BJ; Molkentin JD
Mol Cell Biol; 2005 Feb; 25(3):865-78. PubMed ID: 15657416
[TBL] [Abstract][Full Text] [Related]
14. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
Vallo S; Michaelis M; Gust KM; Black PC; Rothweiler F; Kvasnicka HM; Blaheta RA; Brandt MP; Wezel F; Haferkamp A; Cinatl J
BMC Res Notes; 2016 Sep; 9(1):454. PubMed ID: 27677700
[TBL] [Abstract][Full Text] [Related]
16. MEK1 and MEK2 regulate distinct functions by sorting ERK2 to different intracellular compartments.
Skarpen E; Flinder LI; Rosseland CM; Orstavik S; Wierød L; Oksvold MP; Skålhegg BS; Huitfeldt HS
FASEB J; 2008 Feb; 22(2):466-76. PubMed ID: 17928366
[TBL] [Abstract][Full Text] [Related]
17. PAK1 primes MEK1 for phosphorylation by Raf-1 kinase during cross-cascade activation of the ERK pathway.
Coles LC; Shaw PE
Oncogene; 2002 Mar; 21(14):2236-44. PubMed ID: 11948406
[TBL] [Abstract][Full Text] [Related]
18. Examining Ligand-Based Stabilization of Proteins in Cells with MEK1 Kinase Inhibitors.
Auld DS; Davis CA; Jimenez M; Knight S; Orme JP
Assay Drug Dev Technol; 2015 Jun; 13(5):266-76. PubMed ID: 26107610
[TBL] [Abstract][Full Text] [Related]
19. Thermodynamics of nucleotide and non-ATP-competitive inhibitor binding to MEK1 by circular dichroism and isothermal titration calorimetry.
Smith CK; Windsor WT
Biochemistry; 2007 Feb; 46(5):1358-67. PubMed ID: 17260965
[TBL] [Abstract][Full Text] [Related]
20. Correction: SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Clin Cancer Res; 2016 Dec; 22(24):6302. PubMed ID: 27980026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
